The reaction was monitored by HPLC system to confirm the formation of N-glutaryl LND. scarified and its sera were collected. The IgG portion was isolated and purified by affinity chromatography on protein A column. The specificity of the purified antibody for LND was evaluated by indirect competitive ELISA using dexamethasone like a competitor as it is used with LND inside a combination therapy. == Conclusions == The high affinity of the antibody (IC50= 10 ng/mL) will become useful in the development of an immunoassay system for the dedication of plasma LND concentrations. Current study is going to optimize the assay conditions and validate the methods for the routine application in medical laboratories. Keywords:Multiple myeloma, Lenalidomide, Polyclonal antibody, ELISA, Restorative monitoring, Pharmacokinetic studies == Background == Cancer is one of the greatest health concerns, as it is the principal cause of mortality among men and women worldwide; it accounted for 7.4 million deaths (around 13% of all deaths each year). Deaths from cancer worldwide are projected to continue rising, with an estimated 12 million deaths in 2030 [1]. Multiple myeloma (MM) is definitely a B-cell malignancy characterized by proliferation of monotypic plasma cells. It is the second most common hematological malignancy; approximately 20,000 NVP-BKM120 Hydrochloride instances of MM have been diagnosed in 2007 [2]. The hallmark of MM is the production of a homogeneous immunoglobulin portion, called myeloma protein, from the malignant plasma cells [3]. Pathologic bone damage is the most characteristic feature of MM and is caused by the production of NVP-BKM120 Hydrochloride osteoclastic factors from the malignant plasma cells. Bone pain is the predominant showing symptoms, but additional symptoms such as anemia, hypercalcemia, renal insufficiency, neuropathy, and spinal cord compression may be present at the time of analysis. The classical triad of symptoms is definitely plasmacytosis (> 30% of plasma cells in the bone marrow), myeloma protein either in the urine or blood, and lytic bone lesions [3,4]. MM is definitely ultimately fatal with most individuals relapsing after an initial response to the conventional chemotherapy. Autologous stem cell transplantation and melphalan have long term overall survival rates in patient populations, but most individuals eventually succumb to a refractory form NVP-BKM120 Hydrochloride of the disease. In the 1990s, thalidomide (Thalomid, Celgene Corporation) was used empirically in treatment of MM based on its antiangiogenic activity and medical activity in refractory or relapsed myeloma [5]. However, thalidomide offers significant and dose-limiting somnolence, constipation, neuropathy, and teratogenicity [6]. These harmful effects promoted the search for more potent but less harmful thalidomide derivatives [7]. Lenalidomide (LND) NVP-BKM120 Hydrochloride is definitely a potent novel thalidomide analog which proven remarkable medical activity against myeloma cells [8-12] via a multiple-pathways mechanism [7,13-17]. The strong evidences-based medical success of LND in individuals has led to its recent authorization by US-FDA under the trade name of Revlimid pills by Celgene Corporation [18]. Lenalidomide has a more improved side effects profile than its Rabbit Polyclonal to SMUG1 parent compound thalidomide, however, it causes some dose-dependent side effects such as thrombocytopenia, venous thromboembolism, and myelosuppression [19,20]. These side effects can be handled by combination therapy and/or careful dose adjustment [21,22]. Because LND is definitely primarily excreted via kidneys, individuals with renal insufficiency or failure must be dose modified to prevent the exacerbation of its myelosuppressive effects [9,16]. Because of the structural connection of LND to thalidomide, a teratogenic effect can not ruled out, therefore effective contraception must be used by female individuals [23,24]. Furthermore, studies showed large inter-individual pharmacokinetic variability with concentrationtoxicity relationship [25]. For these reasons, a risk management, monitoring blood counts, and therapeutic drug monitoring are required to achieve the highest therapeutic benefits of LND and prevent its fatal complications [8,26,27]. However, the restorative profile of LND is definitely anticipated to encourage the development of fresh pharmaceutical preparations for LND. As a consequence, there is an increasing demand for appropriate analytical systems for dedication of pharmacokinetic guidelines in bioequivalence studies for LND, as well as with its restorative monitoring. Extensive literature survey showed that there were only two methods for the dedication of LND in plasma [28,29]. These two methods involved liquid chromatography-coupled.
The reaction was monitored by HPLC system to confirm the formation of N-glutaryl LND